<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Chem Phys Lett</journal-id><journal-id journal-id-type="iso-abbrev">Chem Phys Lett</journal-id><journal-title-group><journal-title>Chemical Physics Letters</journal-title></journal-title-group><issn pub-type="ppub">0009-2614</issn><issn pub-type="epub">0009-2614</issn><publisher><publisher-name>Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7540197</article-id><article-id pub-id-type="pii">S0009-2614(20)30982-9</article-id><article-id pub-id-type="doi">10.1016/j.cplett.2020.138068</article-id><article-id pub-id-type="publisher-id">138068</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Identification of potential inhibitors of SARS-CoV-2 papain-like protease from tropane alkaloids from Schizanthus porrigens: A molecular docking study</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Alfaro</surname><given-names>Marco</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Alfaro</surname><given-names>Ignacio</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au015"><name><surname>Angel</surname><given-names>Constanza</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af015" ref-type="aff">c</xref></contrib><aff id="af005"><label>a</label>Departamento de Qu&#x000ed;mica, Campus Andr&#x000e9;s Bello, Facultad de Ciencias, Universidad de La Serena, Colina el Pino S/N, La Serena, Chile</aff><aff id="af010"><label>b</label>Instituto de Investigaci&#x000f3;n Multidisciplinario en Ciencia y Tecnolog&#x000ed;a, Universidad de La Serena, Colina el Pino S/N, La Serena, Chile</aff><aff id="af015"><label>c</label>Centro de Investigaci&#x000f3;n CENBIOEL, La Serena, Chile</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author at: Departamento de Qu&#x000ed;mica, Campus Andr&#x000e9;s Bello, Facultad de Ciencias, Universidad de La Serena, Colina el Pino S/N, La Serena, Chile.</corresp></author-notes><pub-date pub-type="pmc-release"><day>7</day><month>10</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>16</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>7</day><month>10</month><year>2020</year></pub-date><volume>761</volume><fpage>138068</fpage><lpage>138068</lpage><history><date date-type="received"><day>3</day><month>8</month><year>2020</year></date><date date-type="rev-recd"><day>2</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>5</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="graphical" id="ab005"><title>Graphical abstract</title><fig id="f0045" position="anchor"><graphic xlink:href="ga1_lrg"/></fig></abstract><abstract abstract-type="author-highlights" id="ab010"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="o0005"><label>&#x02022;</label><p id="p0005">Antivirals against SARS-CoV-2 are needed.</p></list-item><list-item id="o0010"><label>&#x02022;</label><p id="p0010">The papain-like protease represents an important target for antivirals.</p></list-item><list-item id="o0015"><label>&#x02022;</label><p id="p0015">We investigated tropane alkaloids from Schizanthus porrigens.</p></list-item><list-item id="o0020"><label>&#x02022;</label><p id="p0020">By molecular docking and MS simulations we identified two leads.</p></list-item><list-item id="o0025"><label>&#x02022;</label><p id="p0025">Shizanthine Z has favorable ADME properties and can be considered a lead.</p></list-item></list></p></abstract><abstract id="ab015"><p>This paper presents identification of potential inhibitors of SARS-CoV-2 papain-like protease from tropane alkaloids from Schizanthus porrigens, using molecular docking method. Binding affinities were compared with those obtained with Lopinavir as a SARS-CoV-2 papain-like protease inhibitor. Overall, our findings indicate that Schizanthine Z binds to the SARS-CoV-2 papain-like protease with relatively high affinity and favorable ADME properties. Therefore, Schizanthine Z may represent an appropriate compound for further evaluation in antiviral assays.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>Tropane alkaloids</kwd><kwd>Schizanthus porrigens</kwd><kwd>Molecular docking</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0030">Coronavirus disease 2019 COVID-19 causes severe acute respiratory syndrome (SARS), and therefore this new virus has been given the name severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) <xref rid="b0005" ref-type="bibr">[1]</xref>. Coronaviruses non-structural polyprotein is processed by two proteases, the main protease (Mpro) and the papain-like protease (PLpro), inhibition of PLpro affects virus replication through poor viral protein processing and can also affect activities of other PLpro <xref rid="b0010" ref-type="bibr">[2]</xref>. Other PLpro that can be affected are desubiquitination proteases, which recognize ubiquitin through an enzymatic ubiquitin binding site and can specifically bind and cleave polyubiquitin by binding to diubiquitin through the ubiquitin active site, in contrast, SARS PLpro recognizes Lys48 bound polyubiquitin through ubiquitin binding sites and is, therefore, capable of directly removing Lys48 bound diubiquitin from substrates <xref rid="b0015" ref-type="bibr">[3]</xref>. Maiti (2020) reports that the PLpro encoded by SARS-CoV-2 has a labile Zn site formed by the amino acids Cys189, Cys192, Cys224 and Cys226 and a classic catalytic site formed by the amino acids Cys111, His272 and Asp286, which play key functions for viral replication and represents promising drug targets, because sulfur-based drugs such as peptide-based inhibitors can block Cys residues at the catalytic site or Zn site of CoV-2-PLpro, which leads to CoV-2-PLpro dysfunction and thus stops viral replication <xref rid="b0020" ref-type="bibr">[4]</xref>. Moreover, de-ISGylation proteases <xref rid="b0025" ref-type="bibr">[5]</xref> and innate anti-host immunity reactions can also be affected, PLpro comprises a central catalytic domain and the ubiquitin-like domain, which interferes with the host's antiviral pathways and modulates the immune response of the host, furthermore PLpro subdomains showed different reaction patterns in presence or absence of ubiquitin, lastly, it should be mentioned that PLpro was an important drug target against several Coronaviruses, including MERS CoV <xref rid="b0010" ref-type="bibr">[2]</xref>. Freitas et al (2020) reported that naphthalene-based PLpro inhibitors are effective against SARS-CoV-2 <xref rid="b0030" ref-type="bibr">[6]</xref>, other researchers have also reported that a naphthalene derivative inhibited SARS-CoV-2 PLpro <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>. Due to the above, the search for new drug prospects is the most reliable option to design an efficient therapy for infected patients without delay <xref rid="b0040" ref-type="bibr">[8]</xref>, because the development of vaccines against the SARS-CoV-2 virus can take many months. Furthermore, virus-encoded peptide-based vaccines may not be effective against future coronavirus epidemics, as virus mutations could render them useless <xref rid="b0045" ref-type="bibr">[9]</xref>. In the pharmaceutical industry the development and discovery of new drugs is the main driver of it. In the past, the design of drugs was directly related to Chemistry of natural products, which were later modified by organic synthesis. Currently, the development of more powerful and efficient computers has allowed the generation of methodologies and simulations that have optimized this process <xref rid="b0050" ref-type="bibr">[10]</xref>. However, Natural Products Chemistry continues to be a source for obtaining drugs, for example, S. porrigens Graham is an herbaceous plant that grows only in humid soils in northern Chile (IV Region) <xref rid="b0055" ref-type="bibr">[11]</xref>. Studies on Schizanthus have shown that a series of tropane-derived alkaloids accumulate in this genus <xref rid="b0060" ref-type="bibr">[12]</xref>, which have anticholinergic activity <xref rid="b0065" ref-type="bibr">[13]</xref>, antiemetic <xref rid="b0070" ref-type="bibr">[14]</xref>, anesthetics <xref rid="b0075" ref-type="bibr">[15]</xref>, mydriatics <xref rid="b0080" ref-type="bibr">[16]</xref>, antispasmodics <xref rid="b0085" ref-type="bibr">[17]</xref>, bronchodilators <xref rid="b0090" ref-type="bibr">[18]</xref> and antivirals <xref rid="b0095" ref-type="bibr">[19]</xref>. Species Schizanthus porrigens, native to Chile and Argentina <xref rid="b0100" ref-type="bibr">[20]</xref>, was chosen as source of potential inhibitors for SARS-CoV-2 papain-like protease, which have not yet been investigated, choosing molecular docking for carry out the investigation in silico of tropane alkaloids of Schizanthus porrigens since this method predicts the orientation of a ligand that binds to a protein forming a stable complex and the strength of the bonds generated between them <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>. Molecular docking is one of the most frequently used methods in the design of structure-based drugs, due to the ability to predict the conformation of the ligand to the binding site <xref rid="b0115" ref-type="bibr">[23]</xref>. Kandeel et al (2020) investigated PLpro use of SARS-CoV-2 to select virtually 1,697 FDA-approved clinical drugs, finding that Losartan, Montelukast Sodium, Quercitrin, Zanamivir, NAD1, Candesartan, Chlorhexidine chlorhydrate and Fostamatinib disodium exhibited binding energy superiors to &#x02212;7.5&#x000a0;kcal/mol <xref rid="b0010" ref-type="bibr">[2]</xref>, and within the natural compounds Laskar and Choudhury (2020) repot Baicalin, Quercetin, Licoleafol, Biopterin, Luteolin and Rutin with binding energy equal to or greater than &#x02212;25&#x000a0;kcal/mol <xref rid="b0120" ref-type="bibr">[24]</xref>. The characterization of the protein ligand bond in the cases of viral proteins plays an important role in the search for drugs <xref rid="b0125" ref-type="bibr">[25]</xref>. Thus the objective of this work was the identification of potential inhibitors of SARS-CoV-2 papain-like protease from tropane alkaloids from Schizanthus porrigens using molecular docking.</p></sec><sec id="s0010"><label>2</label><title>Materials and methods</title><p id="p0035">SARS-CoV-2 papain-like protease is essential for virus maturation and infectivity <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>. The crystalline structure of the papain-like protease was obtained from the Protein Data Bank (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/" id="ir010">https://www.rcsb.org/</ext-link>) code 6WX4 <xref rid="b0140" ref-type="bibr">[28]</xref>. The water molecules together with the VIR251 ligand were removed and then the hydrogen atoms were added to the protein to correct the ionization of the amino acid residues of the protein using the Discovery Studio 2020 Client program <xref rid="b0145" ref-type="bibr">[29]</xref>, in order to prepare the protein to effect molecular docking. The obtained protein was saved in pdb format and imported into the PyRx program <xref rid="b0150" ref-type="bibr">[30]</xref> to perform the molecular docking, which was carried out with the Autodock Vina program <xref rid="b0150" ref-type="bibr">[30]</xref>. <xref rid="f0005" ref-type="fig">Fig. 1</xref>
shows complex between SARS-CoV-2 papain-like protease and inhibitor VIR251. <xref rid="f0010" ref-type="fig">Fig. 2</xref>
shows the 2D structure of tropane alkaloids from Schizanthus porrigens, which were imported from the ChemDraw 3D program <xref rid="b0155" ref-type="bibr">[31]</xref> in sdf format. The most stable conformer was determined with the PyPx program <xref rid="b0150" ref-type="bibr">[30]</xref>, then the ADME properties (Absorption, Distribution, Metabolism, and Excretion) were analyzed using the SwissADME database (<ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch/" id="ir015">http://www.swissadme.ch/</ext-link>) <xref rid="b0160" ref-type="bibr">[32]</xref>. Since the main objective in molecular docking is to evaluate protein&#x02013;ligand interactions to predict binding affinity <xref rid="b0165" ref-type="bibr">[33]</xref>, Autodock Vina <xref rid="b0170" ref-type="bibr">[34]</xref> and PyRx <xref rid="b0150" ref-type="bibr">[30]</xref> were used to determine the orientations of the ligands in the active site of SARS-CoV-2 papain-like protease, according to those reported by Rut et al. (2020), deep hydrophobic pocket formed by the residues Asp164, Met208, Pro247, Pro248, Tyr264, Tyr268, Tyr273 y Thr301 was considered as active site <xref rid="b0140" ref-type="bibr">[28]</xref>. Discovery Studio 2020 Client software <xref rid="b0145" ref-type="bibr">[29]</xref> was used to determine and illustrate the intermolecular interactions between tropane alkaloids and residues of active site SARS-CoV-2 papain-like protease. The molecular dynamics simulation was performed using NAMD v.2.14 <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref> with CHARMM36 force field <xref rid="b0185" ref-type="bibr">[37]</xref>, <xref rid="b0190" ref-type="bibr">[38]</xref>, <xref rid="b0195" ref-type="bibr">[39]</xref>. Then each structure was converted to a psf protein structure file by automatic psf generation plugin within the VMD v program. 1.9.3 <xref rid="b0200" ref-type="bibr">[40]</xref>. The simulation was carried out with 5000 steps that were carried out for all the atoms of the system to ensure the elimination of any residual steric shock <xref rid="b0205" ref-type="bibr">[41]</xref>. Then, the structure was simulated at a constant temperature of 310&#x000a0;K and a pressure of 1&#x000a0;atm using Langevin dynamics <xref rid="b0210" ref-type="bibr">[42]</xref>.<fig id="f0005"><label>Fig. 1</label><caption><p>Complex between the papain-like protease of SARS-CoV-2 and the crystallized inhibitor VIR251. Source Protein Data Bank (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/" id="ir005">https://www.rcsb.org/</ext-link>) code 6WX4.</p></caption><graphic xlink:href="gr1_lrg"/></fig><fig id="f0010"><label>Fig. 2</label><caption><p>2D structure of tropane alkaloids from Schizanthus porrigens.</p></caption><graphic xlink:href="gr2_lrg"/></fig></p></sec><sec id="s0015"><label>3</label><title>Results and discussion</title><p id="p0040">Binding affinities and major interactions between SARS-CoV-2 papain-like protease and tropane alkaloids from Schizanthus porrigens were obtained using Autodock Vina. Binding affinities were compared with those obtained with Lopinavir as inhibitor of the SARS-CoV-2 papain-like protease. The binding affinity obtained from 6WX4 binding with the Lopinavir and tropane alkaloids from Schizanthus porrigens are shown in <xref rid="t0005" ref-type="table">Table 1</xref>
. The binding affinity values vary from &#x02212;5.6 to &#x02212;7.5&#x000a0;kcal/mol. Discovery Studio 2020 Client software was used to illustrate the molecular interactions between active site SARS-CoV-2 papain-like protease and the ligands. The ligands showed the expected interactions with the amino acids present in active site of protein, which implies powerful antagonistic properties towards SARS-CoV-2 papain-like protease. Exhibiting the highest binding affinity Schizantina Z with a value of &#x02212;7.5&#x000a0;kcal/mol followed by Schizantina Y with a binding energy value of &#x02212;7.1&#x000a0;kcal/mol. The ligands with the lowest values obtained in this study correspond to ligands 3 and 4 with binding affinity that &#x02212;5.7&#x000a0;kcal/mol and &#x02212;5.6&#x000a0;kcal/mol respectively. In general, the binding affinity values of Schizantin Z and Schizantin Y obtained from the set of 4 tropane alkaloids from Schizanthus porrigens suggest that they can be used as potential inhibitors of SARS-CoV-2 papain-like protease. The binding energies of all compounds are close to that of the reference ligand, except for compounds 3 and 4. As shown in <xref rid="f0015" ref-type="fig">Fig. 3</xref>, <xref rid="f0020" ref-type="fig">Fig. 4</xref>, <xref rid="f0025" ref-type="fig">Fig. 5</xref>, <xref rid="f0030" ref-type="fig">Fig. 6</xref>
complexes between ligands and receptor are stabilized mainly by hydrogen bonds, where the ligand can act as electron acceptor, like in the case of Schizanthine Z or a simultaneous donor and acceptor as in the case of Schizanthine Y, however, other interactions such as hydrophobic interactions also contribute to the stability of the complexes <xref rid="b0165" ref-type="bibr">[33]</xref>. <xref rid="t0010" ref-type="table">Table 2</xref>
shows that all of tropane alkaloids from Schizanthus porrigens that form hydrogen bonds with the key amino acid residues of SARS-CoV-2 papain-like protease. Natural products provide a source for the development of new antiviral drugs <xref rid="b0215" ref-type="bibr">[43]</xref>. Identifying the antiviral mechanisms of these natural agents has shed light on where they interact with the virus life cycle, such as viral entry, replication, assembly, and release, as well as on the goal of virus-specific interactions and host <xref rid="b0165" ref-type="bibr">[33]</xref>. In the present work, we summarize the antiviral activity of tropane-derived alkaloids present in the shrub plant Schizanthus porrigens that grows in soils in northern Chile (IV Region) <xref rid="b0055" ref-type="bibr">[11]</xref> and perform molecular docking of these compounds. (four ligands) with the SARS-CoV-2 papain-like protease to identify possible inhibitors of this, as well as the ADME analysis <xref rid="b0160" ref-type="bibr">[32]</xref>. This is vital since several proteins have recently been described that play a key role in SARS-CoV-2 virus infection and that are considered possible pharmacological targets. These include in addition to the SARS-CoV-2 papain-like protease considered in the present study, the SARS-CoV-2 main protease Mpro <xref rid="b0035" ref-type="bibr">[7]</xref>, RNA-dependent RNA polymerase (NPS12) <xref rid="b0220" ref-type="bibr">[44]</xref>, spike glycoprotein (S) <xref rid="b0080" ref-type="bibr">[16]</xref>, transmembrane protease serine 2 (TMPRSS2) <xref rid="b0225" ref-type="bibr">[45]</xref> and angiotensin-converting enzyme 2 (ACE2) <xref rid="b0230" ref-type="bibr">[46]</xref> among others. Therefore, it should be borne in mind that the best candidate for a drug against SARS-CoV-2 is the molecule that can specifically bind to one of the pharmacological targets mentioned above to form a thermodynamically stable complex, this is a compound with the energy of highest possible binding expressed in terms of Gibbs free energy variation (&#x00394;G) <xref rid="b0165" ref-type="bibr">[33]</xref>. Lipinski's rule of five <xref rid="b0235" ref-type="bibr">[47]</xref> and ADME properties <xref rid="b0235" ref-type="bibr">[47]</xref> which were obtained from SwissADME see <xref rid="t0015" ref-type="table">Table 3</xref>, <xref rid="t0020" ref-type="table">Table 4</xref>
. The results of virtual detection of two tropane alkaloids from Schizanthus porrigens based on molecular docking scores, hydrogen bridge interactions, and Lipinski's rule of five suggest that they are potential inhibitors of the major protease SARS-CoV-2 papain-like protease, which is essential for virus maturation and infectivity <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>. Schizanthine Z is the best drug candidate between the two successes since, in addition to fully obeying Lipinski's rules, it exhibits the highest binding energy. Schizanthine Z, being the one with the highest docking score and the most favorable pharmacokinetics was subjected to a molecular dynamics simulation. Schizanthine Y was also subjected to a molecular dynamics simulation since it was the next best candidate. <xref rid="f0035" ref-type="fig">Fig. 7</xref>
shows a water box simulations using molecular dynamics simulation of Schizanthine Z and Schizanthine Y papain-like protease complexes of SARS-CoV-2 <xref rid="b0010" ref-type="bibr">[2]</xref>. <xref rid="f0040" ref-type="fig">Fig. 8</xref>
shows the mean square deviation (RMSD), which was used to examine the structural changes of the Schizanthine Z and Schizanthine Y papain-like protease complexes of SARS-CoV-2, both graphs show a similar deviation and fluctuation, validating the consistency of the simulation trajectories <xref rid="b0205" ref-type="bibr">[41]</xref>.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Binding affinity (kcal/mol) of 6WX4 and Ligands.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Receptor PDB ID</th><th>Ligands</th><th>Binding Affinity (&#x00394;G in kcal/mol)</th></tr></thead><tbody><tr><td>6WX4</td><td>Schizanthine Y</td><td>&#x02212;7.1</td></tr><tr><td/><td>Schizanthine Z</td><td>&#x02212;7.5</td></tr><tr><td/><td>3</td><td>&#x02212;5.7</td></tr><tr><td/><td>4</td><td>&#x02212;5.6</td></tr><tr><td/><td>Lopinavir (Ref. ligand)</td><td>&#x02212;7.0</td></tr></tbody></table></table-wrap><fig id="f0015"><label>Fig. 3</label><caption><p>(a) H-bonding interactions between the Schizanthine Z with papain-like protease of SARS-CoV-2 target; (b) All types of interactions between the Schizanthine Z with papain-like protease of SARS-CoV-2.</p></caption><graphic xlink:href="gr3_lrg"/></fig><fig id="f0020"><label>Fig. 4</label><caption><p>(a) H-bonding interactions between the Schizanthine Y with papain-like protease of SARS-CoV-2 target; (b) All types of interactions between the Schizanthine Y with papain-like protease of SARS-CoV-2.</p></caption><graphic xlink:href="gr4_lrg"/></fig><fig id="f0025"><label>Fig. 5</label><caption><p>(a) H-bonding interactions between the Compound 3 with papain-like protease of SARS-CoV-2 target; (b) All types of interactions between the Compound 3 with papain-like protease of SARS-CoV-2.</p></caption><graphic xlink:href="gr5_lrg"/></fig><fig id="f0030"><label>Fig. 6</label><caption><p>(a) H-bonding interactions between the Compound 4 with papain-like protease of SARS-CoV-2 target; (b) All types of interactions between the Compound 4 with papain-like protease of SARS-CoV-2.</p></caption><graphic xlink:href="gr6_lrg"/></fig><table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Amino acids residues involved in H-bonds in both ligands and receptors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Ligands</th><th>Amino acids with H-bonds</th></tr></thead><tbody><tr><td>Schizanthine Y</td><td>TYR164, TYR168, TYR173</td></tr><tr><td>Schizanthine Z</td><td>TYR164, TYR173,</td></tr><tr><td>3</td><td>ASP164, TYR164, TYR173</td></tr><tr><td>4</td><td>ASP164</td></tr><tr><td>Lopinavir</td><td>TYR168, GLN269</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0015"><label>Table 3</label><caption><p>Lipinski parameters for dataset from SwissADME.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Inhibitor</th><th>MW</th><th>Log P</th><th>HBD</th><th>HBA</th><th>Violation</th><th>Yes/No</th><th>Solubility</th><th>Log S</th></tr></thead><tbody><tr><td>Schizanthine Y</td><td>490,59</td><td>4,52</td><td>1</td><td>9</td><td>0</td><td>Yes</td><td>M.S.</td><td>&#x02212;4.62</td></tr><tr><td>Schizanthine Z</td><td>490.59</td><td>4.33</td><td>1</td><td>9</td><td>0</td><td>Yes</td><td>M.S.</td><td>&#x02212;4.71</td></tr><tr><td>3</td><td>239.31</td><td>2,51</td><td>1</td><td>4</td><td>0</td><td>Yes</td><td>S</td><td>&#x02212;2.20</td></tr><tr><td>4</td><td>239.31</td><td>2,51</td><td>1</td><td>4</td><td>0</td><td>Yes</td><td>S</td><td>&#x02212;2.46</td></tr></tbody></table><table-wrap-foot><fn><p>MW: Molecular weight (Da), Log P: Octanol-water partition coefficient, HBD: Hydrogen bond donors, HBA: Hydrogen bond acceptors Log S: 10-based logarithm of the solubility measured in mol/l unit.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0020"><label>Table 4</label><caption><p>Pharmacokinetics of the four potential inhibitors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Inhibitor</th><th>GIa</th><th>BBBp</th><th>P-gps</th><th>1A2</th><th>2C19</th><th>2C9</th><th>2D6</th><th>3A4</th><th>Log Kp</th></tr></thead><tbody><tr><td>Schizanthine Y</td><td>High</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>&#x02212;7.34</td></tr><tr><td>Schizanthine Z</td><td>High</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>&#x02212;7.28</td></tr><tr><td>3</td><td>High</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>&#x02212;6.65</td></tr><tr><td>4</td><td>High</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>&#x02212;6.48</td></tr></tbody></table></table-wrap><fig id="f0035"><label>Fig. 7</label><caption><p>(a) Water box simulation using molecular dynamics simulation of complex between the papain-like protease of SARS-CoV-2 and the Schizanthine Z. (b) Water box simulation using molecular dynamics simulation of complex between the papain-like protease of SARS-CoV-2 and the Schizanthine Y.</p></caption><graphic xlink:href="gr7_lrg"/></fig><fig id="f0040"><label>Fig. 8</label><caption><p>(a) The Root Mean Square Deviation (RMSD) curve of complex between the papain-like protease of SARS-CoV-2 and the Schizanthine Z. (b) The Root Mean Square Deviation (RMSD) curve of complex between the papain-like protease of SARS-CoV-2 and the Schizanthine Y.</p></caption><graphic xlink:href="gr8_lrg"/></fig></p></sec><sec id="s0020"><label>4</label><title>Conclusions</title><p id="p0045">The development of new drugs to treat COVID-19 is of vital importance to design an efficient therapy, because development of vaccines against SARS-CoV-2 virus can take many months. Furthermore, virus-encoded peptide-based vaccines may not be effective against future coronavirus epidemics, as virus mutations could render them useless. While researchers are looking for molecules with anti-SARS-CoV-2 activity using organic synthesis techniques, another way is to promote chemistry research on natural products. Considering the enormous amount of existing phytocomposites, we can refer to computational chemistry to help in the study of different plant activities such as Schizanthus porrigens candidates from the set of 4 tropane alkaloids from Schizanthus porrigens using molecular docking and ADME properties. The reactivity of SARS-CoV-2 papain-like protease with 4 tropane alkaloids from Schizanthus porrigens showed that the most stable complex is obtained with Schizanthine Z with a binding affinity value of &#x02212;7.5&#x000a0;kcal/mol, followed by Schizanthine Y with &#x02212;7.1&#x000a0;kcal/mol. Finally, Lipinski's rule of five based on ADME analysis and molecular dynamics simulation confirms that Schizanthine Z is the best candidate for the drug, which is why it is recommended for in vitro tests.</p></sec><sec id="s0025"><title>CRediT authorship contribution statement</title><p id="p0050">
<bold>Marco Alfaro:</bold> Conceptualization, Data curation, Formal analysis, Methodology, Writing - original draft, Writing - review &#x00026; editing. <bold>Ignacio Alfaro:</bold> Conceptualization, Data curation, Formal analysis, Methodology, Resources, Software, Writing - original draft, Writing - review &#x00026; editing. <bold>Constanza Angel:</bold> Resources, Software, Writing - original draft, Writing - review &#x00026; editing.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0055">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Chhikara</surname><given-names>F.</given-names></name><name><surname>Rathi</surname><given-names>B.S.</given-names></name><name><surname>Singh</surname><given-names>B.</given-names></name><name><surname>Poonam</surname><given-names>J.</given-names></name></person-group><article-title>Corona virus SARS-CoV-2 disease COVID-19: infection, prevention and clinical advances of the prospective chemical drug therapeutics</article-title><source>Chem. Biol. Lett.</source><volume>7</volume><issue>1</issue><year>2020</year><fpage>63</fpage><lpage>72</lpage></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Kandeel</surname><given-names>M.</given-names></name><name><surname>Abdelrahman</surname><given-names>A.H.M.</given-names></name><name><surname>Oh-hashi</surname><given-names>K.</given-names></name><name><surname>Ibrahim</surname><given-names>A.</given-names></name><name><surname>Katharigatta</surname><given-names>N.</given-names></name></person-group><article-title>Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Klemm</surname><given-names>T.</given-names></name></person-group><article-title>Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV- 2</article-title><source>EMBO J.</source><volume>39</volume><year>2020</year><fpage>1</fpage><lpage>17</lpage></element-citation></ref><ref id="b0020"><label>4</label><mixed-citation publication-type="other" id="h0020">B. K. Maiti, Can Papain-like Protease Inhibitors Halt SARS-CoV &#x02011; 2 Replication?, (1) (2020), 2&#x02013;4.</mixed-citation></ref><ref id="b0025"><label>5</label><mixed-citation publication-type="other" id="h0025">K. Ratia, A. Kilianski, Y. M. Baez-santos, S. C. Baker, A. Mesecar, Structural basis for the ubiquitin-linkage specificity and deISGylating activity of SARS-CoV papain-like protease, 10 (5) (2014).</mixed-citation></ref><ref id="b0030"><label>6</label><mixed-citation publication-type="other" id="h0030">B.T. Freitas, et al., Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV - 2 papain-like protease, 15 (2020).</mixed-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Peng</surname><given-names>L.</given-names></name><name><surname>Duan</surname><given-names>C.</given-names></name></person-group><article-title>Structure of M pro from SARS-CoV-2 and discovery of its inhibitors</article-title><source>Nature</source><volume>582</volume><year>2020</year><fpage>289</fpage><pub-id pub-id-type="pmid">32272481</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Fantini</surname><given-names>J.</given-names></name><name><surname>Di Scala</surname><given-names>C.</given-names></name><name><surname>Chahinian</surname><given-names>H.</given-names></name><name><surname>Yahi</surname><given-names>N.</given-names></name></person-group><article-title>Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection</article-title><source>Int. J. Antimicrob. Agents J.</source><year>2020</year></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Gurwitz</surname><given-names>D.</given-names></name></person-group><article-title>Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics</article-title><source>Drug Dev. Res.</source><year>2020</year><fpage>2</fpage><lpage>5</lpage></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Prieto-Mart&#x000ed;nez</surname><given-names>J.L.</given-names></name><name><surname>Medina-Franco</surname><given-names>F.D.</given-names></name></person-group><article-title>Dise&#x000f1;o de f&#x000e1;rmacos asistido por computadora: cuando la inform&#x000e1;tica, la qu&#x000ed;mica y el arte se encuentran</article-title><source>TIP Rev. Espec. en Ciencias Qu&#x000ed;mico-Biol&#x000f3;gicas</source><volume>21</volume><issue>2</issue><year>2018</year><fpage>124</fpage><lpage>134</lpage></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Mu&#x000f1;oz</surname><given-names>O.</given-names></name><name><surname>Cort&#x000e9;s</surname><given-names>S.</given-names></name></person-group><article-title>Tropane Alkaloids from Schizanthus porrigens</article-title><source>Pharm. Biol. ISSN</source><volume>36</volume><issue>3</issue><year>1998</year><fpage>162</fpage><lpage>166</lpage></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>O.</given-names></name><name><surname>Humam</surname><given-names>M.</given-names></name><name><surname>Bieri</surname><given-names>M.</given-names></name><name><surname>Christen</surname><given-names>S.</given-names></name><name><surname>Poblete</surname><given-names>P.</given-names></name><name><surname>Munoz</surname><given-names>E.</given-names></name></person-group><article-title>In vitro shoot and root organogenesis, plant regeneration and production of tropane alkaloids in some species of Schizanthus</article-title><source>Phytochemistry</source><volume>67</volume><issue>6</issue><year>2006</year><fpage>570</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">16427668</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Holzman</surname><given-names>R.S.</given-names></name></person-group><article-title>The legacy of Atropos, the fate who cut the thread of life</article-title><source>Anesthesiol. J. Am. Soc. Anesthesiol.</source><volume>89</volume><issue>1</issue><year>1998</year><fpage>241</fpage><lpage>249</lpage></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Grynkiewicz</surname><given-names>G.</given-names></name><name><surname>Gadzikowska</surname><given-names>M.</given-names></name></person-group><article-title>Tropane alkaloids as medicinally useful natural products and their synthetic derivatives as new drugs</article-title><source>Pharmacol. Rep.</source><volume>60</volume><issue>4</issue><year>2008</year><fpage>439</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">18799813</pub-id></element-citation></ref><ref id="b0075"><label>15</label><mixed-citation publication-type="other" id="h0075">R.L. Clarke, The tropane alkaloids, in: The Alkaloids: Chemistry and Physiology, vol. 16, Elsevier, 1977, pp. 83&#x02013;180.</mixed-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>Padoan</surname><given-names>M.</given-names></name><name><surname>Sciacovelli</surname><given-names>A.</given-names></name><name><surname>Basso</surname><given-names>L.</given-names></name><name><surname>Negrini</surname><given-names>D.</given-names></name><name><surname>Zuin</surname><given-names>D.</given-names></name><name><surname>Cosma</surname><given-names>S.</given-names></name><name><surname>Faggian</surname><given-names>C.</given-names></name><name><surname>Matricardi</surname><given-names>D.</given-names></name><name><surname>Plebani</surname><given-names>P.</given-names></name></person-group><article-title>IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study</article-title><source>Clin. Chim. Acta</source><volume>507</volume><year>2020</year><fpage>164</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">32343948</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>El Bazaoui</surname><given-names>A.</given-names></name><name><surname>Bellimam</surname><given-names>A.</given-names></name><name><surname>Lan&#x000e7;ar</surname><given-names>M.A.</given-names></name><name><surname>Soulaymani</surname><given-names>I.T.</given-names></name></person-group><article-title>Gas-liquid chromatography-mass spectrometry investigation of tropane alkaloids in Hyoscyamus albus L. from Morocco Ahmed</article-title><source>Zeitschrift f&#x000fc;r Naturforsch. C</source><volume>67</volume><issue>9&#x02013;10</issue><year>2012</year><fpage>461</fpage><lpage>465</lpage></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Kohnen-johannsen</surname><given-names>K.L.</given-names></name><name><surname>Kayser</surname><given-names>O.</given-names></name></person-group><article-title>Tropane alkaloids: chemistry, pharmacology, biosynthesis and production</article-title><source>Molecules</source><volume>24</volume><issue>4</issue><year>2019</year><fpage>1</fpage><lpage>23</lpage></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>&#x000d6;z&#x000e7;elik</surname><given-names>I.</given-names></name><name><surname>Kartal</surname><given-names>B.</given-names></name><name><surname>Orhan</surname><given-names>M.</given-names></name></person-group><article-title>Cytotoxicity, antiviral and antimicrobial activities of alkaloids, flavonoids, and phenolic acids</article-title><source>Pharm. Biol.</source><volume>49</volume><issue>4</issue><year>2011</year><fpage>396</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">21391841</pub-id></element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Mu&#x000f1;oz-Schick</surname><given-names>A.</given-names></name><name><surname>Moreira-Mu&#x000f1;oz</surname><given-names>M.</given-names></name></person-group><article-title>El g&#x000e9;nero Schizanthus (Solanaceae) en Chile</article-title><source>Rev. Chagual</source><year>2008</year><fpage>21</fpage><lpage>32</lpage></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>R.</given-names></name><name><surname>Mehrotra</surname><given-names>S.</given-names></name></person-group><article-title>An overview of molecular docking</article-title><source>JSM Chem.</source><volume>4</volume><issue>2</issue><year>2016</year><fpage>1024</fpage><lpage>1028</lpage></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Sanghani</surname><given-names>R.</given-names></name><name><surname>Ganatra</surname><given-names>H.V.</given-names></name><name><surname>Pande</surname><given-names>S.H.</given-names></name></person-group><article-title>Molecular &#x02013; docking studies of potent anticancer agent</article-title><source>J. Comput. Sci. Syst. Biol.</source><volume>5</volume><issue>1</issue><year>2020</year><fpage>12</fpage><lpage>15</lpage></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>A.D.</given-names></name><name><surname>Dos Santos</surname><given-names>L.G.</given-names></name><name><surname>Oliva</surname><given-names>R.N.</given-names></name><name><surname>Andricopulo</surname><given-names>G.</given-names></name></person-group><article-title>Molecular docking and structure-based drug design strategies</article-title><source>Molecules</source><volume>20</volume><issue>7</issue><year>2015</year><fpage>13384</fpage><lpage>13421</lpage><pub-id pub-id-type="pmid">26205061</pub-id></element-citation></ref><ref id="b0120"><label>24</label><mixed-citation publication-type="other" id="h0120">M.D. Laskar, M.A. Choudhury, Search for therapeutics against COVID 19 targeting SARS-CoV-2 papain-like protease&#x000a0;: an in silico study, (2020) 1&#x02013;28.</mixed-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name></person-group><article-title>Specific noncovalent interactions at protein-ligand interface: implications for rational drug design</article-title><source>Curr. Med. Chem.</source><volume>19</volume><issue>2</issue><year>2012</year><fpage>226</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">22320300</pub-id></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name></person-group><article-title>Emerging coronaviruses: genome structure, replication, and pathogenesis</article-title><source>J. Med. Virol.</source><volume>92</volume><issue>4</issue><year>2020</year><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">31967327</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Ullrich</surname><given-names>S.</given-names></name><name><surname>Nitsche</surname><given-names>C.</given-names></name></person-group><article-title>The SARS-CoV-2 main protease as drug target</article-title><source>Bioorg. Med. Chem. Lett.</source><volume>30</volume><year>2020</year><object-id pub-id-type="publisher-id">127377</object-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Rut</surname><given-names>S.K.</given-names></name><name><surname>Lv</surname><given-names>W.</given-names></name><name><surname>Zmudzinski</surname><given-names>Z.</given-names></name><name><surname>Patchett</surname><given-names>M.</given-names></name><name><surname>Nayak</surname><given-names>S.</given-names></name><name><surname>Snipas</surname><given-names>D.</given-names></name><name><surname>El Oualid</surname><given-names>S.J.</given-names></name><name><surname>Bekes</surname><given-names>F.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Drag</surname><given-names>T.T.</given-names></name><name><surname>Olsen</surname><given-names>M.</given-names></name></person-group><article-title>Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design</article-title><source>bioRxiv</source><year>2020</year></element-citation></ref><ref id="b0145"><label>29</label><mixed-citation publication-type="other" id="h0145">D.S. Biovia, Discovery studio visualizer, vol. 936, San Diego, CA, USA, 2017.</mixed-citation></ref><ref id="b0150"><label>30</label><mixed-citation publication-type="other" id="h0150">A.J. Dallakyan, S. Olson, Small molecule library screening by docking with PyRx, in: H.C. Hempel, J. Williams, (Eds.) Chemical Biology, Humana Press, New York, 2015, pp. 243&#x02013;250.</mixed-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Wan</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Ouyang</surname><given-names>Y.</given-names></name></person-group><article-title>Personal experience with four kinds of chemical structure drawing software: review on ChemDraw, ChemWindow, ISIS/Draw, and ChemSketch</article-title><source>J. Chem. Inf. Comput. Sci.</source><volume>44</volume><issue>4</issue><year>2004</year><fpage>1886</fpage><lpage>1890</lpage><pub-id pub-id-type="pmid">15446849</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Daina</surname><given-names>V.</given-names></name><name><surname>Michielin</surname><given-names>A.</given-names></name><name><surname>Zoete</surname><given-names>O.</given-names></name></person-group><article-title>SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title><source>Sci. Rep.</source><volume>42717</volume><year>2017</year><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>Mpiana</surname><given-names>D.D.</given-names></name><name><surname>Tshibangu</surname><given-names>P.T.</given-names></name><name><surname>Kilembe</surname><given-names>D.S.</given-names></name><name><surname>Gbolo</surname><given-names>J.T.</given-names></name><name><surname>Mwanangombo</surname><given-names>B.Z.</given-names></name><name><surname>Inkoto</surname><given-names>D.T.</given-names></name><name><surname>Lengbiye</surname><given-names>C.L.</given-names></name><name><surname>Mbadiko</surname><given-names>E.M.</given-names></name><name><surname>Matondo</surname><given-names>C.M.</given-names></name><name><surname>Bongo</surname><given-names>A.</given-names></name><name><surname>Tshilanda</surname><given-names>G.N.</given-names></name></person-group><article-title>Identification of potential inhibitors of SARS-CoV-2 main protease from Aloe vera compounds: a molecular docking study</article-title><source>Chem. Phys. Lett.</source><volume>754</volume><year>2020</year><object-id pub-id-type="publisher-id">137751</object-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>Trott</surname><given-names>A.J.</given-names></name><name><surname>Olson</surname><given-names>O.</given-names></name></person-group><article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title><source>J. Comput. Chem.</source><volume>31</volume><issue>2</issue><year>2009</year><fpage>455</fpage><lpage>461</lpage></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Kal&#x000e9;</surname><given-names>S.K.L.</given-names></name><name><surname>Skeel</surname><given-names>R.</given-names></name><name><surname>Bhandarkar</surname><given-names>M.</given-names></name><name><surname>Brunner</surname><given-names>R.</given-names></name><name><surname>Gursoy</surname><given-names>A.</given-names></name><name><surname>Krawetz</surname><given-names>N.</given-names></name><name><surname>Phillips</surname><given-names>J.</given-names></name><name><surname>Shinozaki</surname><given-names>A.</given-names></name><name><surname>Varadarajan</surname><given-names>K.</given-names></name></person-group><article-title>NAMD2: greater scalability for parallel molecular dynamics</article-title><source>J. Comput. Phys.</source><volume>151</volume><year>1999</year><fpage>283</fpage><lpage>312</lpage></element-citation></ref><ref id="b0180"><label>36</label><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>K.</given-names></name><name><surname>Braun</surname><given-names>J.C.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Gumbart</surname><given-names>W.</given-names></name><name><surname>Tajkhorshid</surname><given-names>J.</given-names></name><name><surname>Villa</surname><given-names>E.</given-names></name><name><surname>Chipot</surname><given-names>E.</given-names></name><name><surname>Skeel</surname><given-names>C.</given-names></name><name><surname>Kale</surname><given-names>R.D.</given-names></name><name><surname>Schulten</surname><given-names>L.</given-names></name></person-group><article-title>Scalable molecular dynamics with NAMD</article-title><source>J. Comput. Chem.</source><volume>26</volume><issue>16</issue><year>2008</year><fpage>1781</fpage><lpage>1802</lpage></element-citation></ref><ref id="b0185"><label>37</label><mixed-citation publication-type="other" id="h0185">B.R. Brooks, R.E. Bruccoleri, B.D. Olafson, D.J. States, S. Swaminathan, M. Karplus, Program for macromolecular energy, minimization, and dynamics calculations, 4 (2) (1983) 187&#x02013;217.</mixed-citation></ref><ref id="b0190"><label>38</label><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Cheng</surname><given-names>J.</given-names></name><name><surname>Swails</surname><given-names>X.</given-names></name><name><surname>Yeom</surname><given-names>J.M.</given-names></name><name><surname>Eastman</surname><given-names>M.S.</given-names></name><name><surname>Lemkul</surname><given-names>P.K.</given-names></name><name><surname>Wei</surname><given-names>J.A.</given-names></name><name><surname>Buckner</surname><given-names>S.</given-names></name><name><surname>Jeong</surname><given-names>J.</given-names></name><name><surname>Qi</surname><given-names>J.C.</given-names></name><name><surname>Jo</surname><given-names>Y.</given-names></name></person-group><article-title>CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field</article-title><source>J. Chem. Theory Comput.</source><volume>12</volume><issue>1</issue><year>2014</year><fpage>405</fpage><lpage>413</lpage></element-citation></ref><ref id="b0195"><label>39</label><mixed-citation publication-type="other" id="h0195">A.D. Mackerell, et al., All-atom empirical potential for molecular modeling and dynamics studies of proteins, 1998.</mixed-citation></ref><ref id="b0200"><label>40</label><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>K.</given-names></name><name><surname>Dalke</surname><given-names>W.</given-names></name><name><surname>Schulten</surname><given-names>A.</given-names></name></person-group><article-title>VMD: visual molecular dynamics</article-title><source>J. Mol. Graph.</source><volume>14</volume><issue>1</issue><year>1996</year><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">8744570</pub-id></element-citation></ref><ref id="b0205"><label>41</label><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>S.</given-names></name><name><surname>Dasgupta</surname><given-names>S.</given-names></name><name><surname>Adhikary</surname><given-names>T.</given-names></name><name><surname>Panja</surname><given-names>S.S.</given-names></name></person-group><article-title>Structural insight to hydroxychloroquine-3C- like proteinase complexation from SARS-CoV-2: inhibitor modelling study through molecular docking and MD-simulation study</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="b0210"><label>42</label><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name><surname>Gullingsrud</surname><given-names>J.</given-names></name><name><surname>Kosztin</surname><given-names>D.</given-names></name><name><surname>Schulten</surname><given-names>K.</given-names></name></person-group><article-title>Structural determinants of MscL gating studied by molecular dynamics simulations</article-title><source>Biophys. J.</source><volume>80</volume><issue>5</issue><year>2001</year><fpage>2074</fpage><lpage>2081</lpage><pub-id pub-id-type="pmid">11325711</pub-id></element-citation></ref><ref id="b0215"><label>43</label><mixed-citation publication-type="other" id="h0215">S. Antonio, S. Moreira, Natural products&#x02019; role against COVID-19, (2020) 23379&#x02013;23393.</mixed-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name><surname>Elfiky</surname><given-names>A.A.</given-names></name></person-group><article-title>SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting : an in silico perspective</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><fpage>1</fpage><lpage>9</lpage></element-citation></ref><ref id="b0225"><label>45</label><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name><surname>Vipul</surname><given-names>K.</given-names></name></person-group><article-title>Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="b0230"><label>46</label><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>A.S.</given-names></name><name><surname>Penninger</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>J.M.</given-names></name><name><surname>Zhong</surname><given-names>Y.</given-names></name><name><surname>Slutsky</surname><given-names>N.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target</article-title><source>Intensive Care Med.</source><volume>46</volume><year>2020</year><fpage>586</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">32125455</pub-id></element-citation></ref><ref id="b0235"><label>47</label><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>C.A.</given-names></name><name><surname>Lombardo</surname><given-names>F.</given-names></name><name><surname>Dominy</surname><given-names>B.W.</given-names></name><name><surname>Feeney</surname><given-names>P.J.</given-names></name></person-group><article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title><source>Adv. Drug Deliv. Rev.</source><volume>23</volume><issue>1&#x02013;3</issue><year>1997</year><fpage>3</fpage><lpage>25</lpage></element-citation></ref></ref-list><sec id="s0035" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary material</title><p id="p0065">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0005"><caption><title>Supplementary data 1</title></caption><media xlink:href="mmc1.xml"/></supplementary-material>
</p></sec><fn-group><fn id="s0030" fn-type="supplementary-material"><label>Appendix A</label><p id="p0060">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cplett.2020.138068" id="ir020">https://doi.org/10.1016/j.cplett.2020.138068</ext-link>.</p></fn></fn-group></back></article>